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ABSTRACT
Introduction Multiparametric MRI (mpMRI) has improved 
risk stratification for men with suspected prostate cancer. 
Indeed, mpMRI- visible tumours tend to be larger and of 
higher pathological grade than mpMRI- invisible tumours; 
however, concern remains around significant cancer that 
is undetected by mpMRI. There has been considerable 
recent interest to investigate whether tumour conspicuity 
on mpMRI is associated with additional histopathological 
features (including cellular density, microvessel density 
and unusual prostate cancer subtypes), which may have 
important clinical implications in both diagnosis and 
prognosis. Furthermore, analysis of these features may 
help reveal the radiobiology that underpins the actual 
mechanisms of mpMRI visibility (and invisibility) of prostate 
tumours. Here, we describe a protocol for a systematic 
review of the histopathological basis of prostate cancer 
conspicuity on mpMRI.
Methods and analysis A systematic search of the 
MEDLINE, PubMed, Embase and Cochrane databases 
will be conducted. The Preferred Reporting Items for 
Systematic Reviews and Meta- Analyses (PRISMA) 
guidelines will be used to guide screening, thematic 
reporting and conclusions drawn from all eligible studies. 
Included papers will be full- text, English- language articles, 
comparing the histopathological characteristics of mpMRI- 
visible lesions and mpMRI- invisible tumours. All studies 
published between January 1950 and January 2020 
will be eligible for inclusion. Studies using confirmatory 
immunohistochemistry for the identification of immune 
subsets or structural components will be included. 
Study bias and quality will be assessed using a modified 
Newcastle- Ottawa scale. To ensure methodological rigour, 
this protocol is written in accordance with the PRISMA 
Protocol 2015 checklist. If appropriate, a meta- analysis 
will be conducted comparing histopathological feature 
frequency between mpMRI- visible and mpMRI- invisible 
disease.
Ethics and dissemination No ethical approval will 
be required as this is an academic review of published 
literature. Findings will be disseminated through 
publications in peer- reviewed journals and presentations 
at national and international conferences.
PROSPERO registration number CRD42020176049
BACKGROUND
The introduction of multiparametric MRI 
(mpMRI) has greatly improved the approach 
to prostate cancer diagnosis, offering 
improved prebiopsy risk stratification.1 Accu-
rate identification of high- risk disease, before 
a biopsy is conducted, enables increased 
detection of significant cancer and reduced 
detection of insignificant cancer, compared 
with traditional diagnostic approaches.2 
However, approximately 10%–20% of clini-
cally significant disease may be overlooked 
by mpMRI.1 3 The mechanisms that underpin 
mpMRI invisibility and the clinical implica-
tions that arise from this phenomenon have 
been the subject of intense research in recent 
years.
Prostate cancer visibility on mpMRI is posi-
tively associated with both tumour size and 
Gleason grade,1 4 which suggests tumour 
conspicuity can provide useful prognostica-
tion, as these pathological features at biopsy 
are typically considered to have the strongest 
Strengths and limitations of this study
 ► This work will represent the first detailed systematic 
review and meta- analysis of the histopathological 
features of multiparametric MRI (mpMRI)- visible 
and mpMRI- invisible prostate cancers following 
the methodological steps of the Preferred Reporting 
Items for Systematic Reviews and Meta- Analyses 
(PRISMA) guidelines.
 ► The level of heterogeneity found between the re-
viewed articles may somewhat limit the generalis-
ability of derived results.
 ► The evidence surrounding important histopatholog-
ical features of mpMRI- visible and mpMRI- invisible 
tumours is growing; however, as this is still a new 
area of research, the strength of the conclusions 
may be limited by finite extant literature.
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impact on clinical outcome. Furthermore, it appears that 
this is corroborated at the molecular level, as mpMRI- 
visible tumours are enriched with genomic features of 
disease aggressivity.5 6 More recently, nuanced microstruc-
tural and pathological features have also been linked with 
disease conspicuity, including cellular and microvessel 
density, cribriform and intraductal cancer patterns, and 
stromal and luminal (to malignant cell) ratios.7–11 Taken 
together, this evidence suggests that the visibility status 
of a tumour on mpMRI may be an indicator of clinical 
risk. Early evidence has shown that low- risk Gleason grade 
group (GGG) 1 tumours with a positive mpMRI at base-
line are at increased risk of intervention, upgrading and 
unfavourable disease at the time of radical prostatec-
tomy, compared with those with GGG1 mpMRI- invisible 
tumours.12 However, mpMRI- targeted biopsy may not be 
insufficient alone to estimate risk of disease progression.13 
As the ability of mpMRI to detect tumours is influenced 
by additional histopathological features, it is pertinent 
to now draw together this expanding radiopathological 
literature to address this important clinical challenge.
The aim of this systematic review was to appraise and 
collate, for the first time, the evidence supporting the 
histopathological basis of tumour visibility and invisibility 
on mpMRI, in order to reveal the potential mechanisms 
that underpin mpMRI conspicuity, and the possible diag-
nostic and prognostic implication of mpMRI phenotypes.
METHODS AND ANALYSIS
This systematic review protocol has been written in line 
with the Preferred Reporting Items for Systematic Reviews 
and Meta- Analyses Protocol (PRISMA) 2015 checklist.14 
Once identified, included studies will undergo analysis 
and thematic synthesis to derive the key histopathological 
elements associated with tumour visibility and invisibility 
on mpMRI.
Search methodology
The MEDLINE, PubMed, Embase and Cochrane data-
bases will be systematically searched in order to retrieve 
all studies that contribute relevant evidence. The search 
strategy will include Medical Subject Headings (MeSH) 
terms, as well as free text, joined with appropriate Boolean 
operators. The search will include the terms ‘prostate,’ 
‘cancer’ and ‘MRI’, as well as multiple synonyms for the 
terms ‘pathology’ and ‘histology’. The selected search 
terms are broad, with high sensitivity for identification 
of relevant studies. To include the maximum number of 
articles, all studies published between January 1950 and 
January 2020 will be eligible. We will expedite the system-
atic review process by uploading all articles to Rayyan, a 
semiautomated tool designed to improve the speed and 
reporting accuracy during the initial screening process 
and to allow three reviewers to filter duplicate studies 
and screen articles for relevance.15 To further improve 
the evidence yield, all included articles will be reference- 
searched manually to identify missed studies or additional 
data. Finally, experts will be consulted to identify addi-
tional literature. In the case of missing or unclear data, 
the corresponding authors will be contacted directly.
Study selection and data extraction
Three researchers will independently screen eligible 
studies, removing irrelevant studies based on titles and 
abstracts. Those studies which pass the initial screen will be 
downloaded and the full- text examined to confirm eligi-
bility. Disagreement between reviewers will be discussed 
until a consensus is reached or a fourth reviewer will be 
consulted. All exclusions will be noted for later analysis 
and the reasons for exclusion documented in detail in 
order to generate the PRISMA flow diagram.
Inclusion criteria
To be included in the analysis, studies must investigate 
one or more histopathological aspects of the appear-
ance of prostate cancer on mpMRI. Investigations may 
be conducted at the macroscopic (eg, tumour size) 
and microscopic (eg, morphological and patholog-
ical patterns) levels; or be based on routine or special 
staining, including immunohistochemistry (eg, confir-
mation of microstructural components, such as CD31 for 
microvessels).
Exclusion criteria
Non- English language articles, conference abstracts, 
review articles, correspondence articles, expert opin-
ions and case reports will be excluded. Studies that do 
not correlate mpMRI phenotypes with histopatholog-
ical features will be excluded. Articles focusing solely 
on molecular characteristics (genetic or transcriptomic) 
or clinical features of mpMRI conspicuity will also be 
removed.
Data extraction
All relevant articles will be carefully read and themes 
extracted. All extracted data will be held on a shared 
datasheet and confirmed by at least three independent 
reviewers to maintain veracity. Data will be collated in a 
manner that we have successfully demonstrated previ-
ously.6 Table 1 summarises data items to be collected.
Endpoints
The primary endpoint will be statistically significant 
differences in quantitative measurements (eg, frequency 
or density) of histopathological features between mpMRI- 
visible and mpMRI- invisible prostate cancers. Secondary 
endpoints will include explanatory links between these 
features and mpMRI conspicuity, as well as the potential 
clinical implications. As study methodology may impact 
estimated frequencies of histopathological features, we 
will include these variables in a moderator analysis (see 
Meta- analysis section).
Risk of bias in individual studies
A modified Newcastle- Ottawa score (originally 
constructed for assessment of observational cohort 
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studies) will be used to score the bias and quality across 
included studies.16 This system is divided into three 
core elements: selection, comparability and outcome. 
Within each section, there are subquestions to evaluate 
the quality of the research methodology, at the study 
level. Three reviewers will be involved with this process, 
and any disagreement will be settled by consensus. The 
outcome of the bias and quality assessment will inform 
the thematic synthesis by providing an assessment of the 
reliability and applicability of the available evidence. If 
studies are deemed to be of excessively low quality (or 
high bias), then these may be excluded or, if included, 
will be accompanied by appropriate commentary in the 
discussion and conclusion. As this review is focused on 
the histopathological characteristics associated with pros-
tate cancer conspicuity on mpMRI (as opposed to treat-
ment outcome), we will modify non- applicable sections of 
the scoring scheme to more closely reflect the nature of 
the evidence base and reduce reporting inaccuracy, in a 
similar approach that we have taken previously.6
Meta-analysis
If there are a sufficient number of studies available (ie, 
over three) that analyse a particular histopathological 
feature using a similar methodology, then we will conduct 
a meta- analysis. The frequency of the histopathological 
feature between mpMRI- visible and mpMRI- invisible 
tumours will be compared. Any analysis will be performed 
as previously described.17 Briefly, numbers of positive 
and negative cases of a particular histopathological 
feature would be extracted from a given study and raw/
direct proportions will be calculated. The distribution 
of untransformed, logit and double arcsine transformed 
proportions will be compared. Whichever distributions 
resemble a normal distribution (assessed using density 
plots and Shapiro- Wilk tests) will be used for further 
analysis.
The model fitted will be determined based on inter-
study variation (measured via I2); if significant, a random- 
effect model will be fitted, or a fixed- effect model if not. 
After fitting a model to all relevant studies, leave- one- out 
(LOO) analyses and accompanying diagnostic plots will 
be used to identify influential studies, including exter-
nally studentised residuals, difference in fits values, 
Cook’s distances, covariance ratios, LOO estimates of the 
amount of heterogeneity, LOO values of the test statistics 
for heterogeneity, hat values and weights. Studies with a 
statistically significant influence on the fitted model will 
be removed as outliers and the model refitted. These 
outliers will be examined for potential confounding vari-
ables such as study methodology or poor interobserver 
agreement for mpMRI scans. Finally, the summary esti-
mates will be compared between mpMRI- visible and 
mpMRI- invisible cancers as subgroups, and the signif-
icance of differences will be assessed. If appropriate, 
moderator analysis will also be performed between 
factors, which may influence the outcome, including, 
but not limited to, study methodology, study size, year of 
publication, cohort type, relevant methodology (such as 
radical prostatectomy vs biopsy studies) or visibility defi-
nition. Analytics will be performed as outlined by Wang.18 
In the event that there is insufficient data to conduct a 
meta- analysis, only thematic synthesis will be performed.
Patient and public involvement
No patients were involved in this study.
DISCUSSION
Over the past decade, mpMRI has been widely adopted as 
the risk stratification tool of choice for men at risk of pros-
tate cancer. This has become particularly true following 
incorporation of prebiopsy mpMRI into national and 
international prostate cancer guidelines.19 20 As such, it 
is now crucial that we better appreciate the characteris-
tics of prostate cancers that are detected and missed by 
mpMRI.4 Through systematic review, we aim to identify 
commonality between pathology- based studies which 
have investigated mpMRI- visible and mpMRI- invisible 
tumours. Our results will enhance the understanding 
of the histopathological features that influence prostate 
cancer visibility on mpMRI, particularly beyond increased 
Gleason grade and high- tumour volume.
Estimates for proportions of significant mpMRI- 
undetected prostate cancer vary between studies21; 
however, it has become clear that microscopic tumour 
composition is likely an important factor in determining 
mpMRI signal (and therefore disease detection). Our 
planned thematic synthesis will assimilate the evidence 
surrounding the microscopic basis of tumour conspi-
cuity, including the following considerations. Diffusion 
Table 1 Data collection items
Item Data title Data type
1 Year of publication Study characteristic
2 Study authors Study characteristic
3 Experimental design Study characteristic
4 Patient population Demographics
5 Study size Demographics
6 mpMRI scoring scheme 
used
Methodology
7 Definition for clinically 
significant disease
Methodology
8 Definition for lesion visibility 
and invisibility
Methodology
9 Sample processing 
approach
Methodology
10 Histopathological feature 
studied
Outcome
11 Differential quantification of 
feature
Outcome
mpMRI, multiparametric MRI.
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of water is a key principle of MRI signal generation; this 
is affected by alterations in tissue microenvironment and 
cellular structure, which may hamper free movement of 
water molecules.22 This concept theoretically explains 
the disparate MRI appearances of the different zones of 
the prostate (including the peripheral zone and normal 
central gland) and is also likely to be crucial in the mpMRI 
visibility of prostate cancer.23 Indeed, an increased archi-
tectural density has been observed in mpMRI- visible 
tumours, with an increased proportion of cancer cells and 
decreased proportions of stroma and luminal spaces.24 
This may, in turn, explain visibility of these tumours on 
mpMRI, through increased restriction of water diffusion 
within dense tumour tissue (thus generating high signal 
on the diffusion weighted mpMRI sequence). Variations 
in tumour density may explain variable ability of mpMRI 
to estimate gross tumour volume and may explain why 
alternate imaging modalities, such as prostate specific 
membrane antigen positron emission tomography/
computed tomography (PSMA- PET/CT), may provide 
more accurate representation of volume by targeting 
tumour- specific markers.25 26 It also appears that mpMRI- 
visible tumours have raised microvessel density,27 which is 
cohesive with genetic studies that also have demonstrated 
an enrichment of vascular endothelial growth factor in 
these tumours.28 29 An increased level of vasculature could 
potentially explain tumour visibility on mpMRI, through 
increased concentrations of mpMRI- contrast agent (gado-
linium) in tumour vessels, thus generating higher MRI 
signal on the dynamic contrast sequence. Finally, there 
is mixed evidence regarding the mpMRI visibility or the 
mpMRI invisibility of particular prostate cancer subtypes, 
including cribriform pattern30 31 and ductal cancer.32 
This is potentially concerning, as these cancer subtypes 
are associated with increased disease aggression and 
poor clinical outcome. Our planned systematic review 
(described in this protocol) will highlight and discuss 
these postulated features, among many others, in detail.
Another major aim of this review was to catalogue 
heterogeneity within this literature. We have recently 
reviewed the genetic landscape that underpins the conspi-
cuity of prostate cancer on mpMRI and found a high 
degree of diversity among study methodologies, radio-
logical scoring systems used and definitions of visibility 
and clinical significance.33 This heterogeneity is further 
complicated by the substantial differences in scan quality 
observed between different centres.34 In this proposed 
review, we will systematically identify sources of hetero-
geneity, which we hope will guide future studies in this 
sphere.
In summary, this systematic review will combine the 
extant evidence in this emerging field, for the first time. 
Collation and analysis of these data will enrich our under-
standing of the additional histopathological factors 
(beyond tumour grade and size) that contribute to the 
conspicuity of prostate cancer on mpMRI. Additionally, 
this process will also help reveal the potential clinical role 
that these factors play in both diagnosis and treatment 
(eg, during planning focal therapy and radiotherapy)35 36 
and will aid identification of important avenues for future 
research.
Trial status
 ► Preliminary searches: started.
 ► Piloting of the study selection process: started.
 ► Formal screening: started.
 ► Data extraction: not started.
 ► Risk of bias assessment: not started.
 ► Data analysis: not started.
Draft of search strategy for MEDLINE, Embase, PubMed and 
Cochrane databases
((((prostat* NOT prostatitis) AND (“cancer” OR tumo?r* 
OR malignancy*)) AND (“MRI” OR “MRI” OR “multi-
parametric MRI” OR “mpMRI” OR “mp- MRI”)) AND 
(patholog* OR histopatholog* OR histo* OR “IHC” OR 
“Immunohistochemistry”)) AND visib*).ti,ab
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